Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$34.71M$34.71M+33.4% vs Q3 2019 Net Income-$98.98M-$98.98MN/M vs Q3 2019 EPS Diluted-$1.43-$1.43N/M vs Q3 2019 Operating Income-$90,327,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$73,411,000N/M Margins · derivedOperating margin-260.3%+158.8 pt vs Q3 2019
Net margin-285.2%+122.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end